While tofacitinib is primarily used to manage intestinal inflammation, its mechanism of action—targeting the JAK-STAT signaling pathway—may also help control systemic inflammation associated with IBD, including arthropathy (12). The gene discussed is SOAT1; the disease is arthropathy.